Login to Your Account



Pharma: Other News To Note


Wednesday, March 28, 2012
• Janssen Therapeutics, of Titusville, N.J., a unit of Johnson & Johnson, said the FDA approved Intelence (etravirine), a non-nucleoside reverse transcriptase inhibitor (NNRTI), for use in combination with other antiretroviral (ARV) medications in HIV-1 treatment-experienced pediatric patients, ages 6 to younger than 18, who are experiencing virologic failure with HIV-1 strains resistant to NNRTIs and other ARVs.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription